<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03893955</url>
  </required_header>
  <id_info>
    <org_study_id>M19-037</org_study_id>
    <secondary_id>2019-000478-45</secondary_id>
    <nct_id>NCT03893955</nct_id>
  </id_info>
  <brief_title>A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors</brief_title>
  <official_title>A Phase 1, Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Combinations of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Subjects With Locally Advanced or Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study evaluating the safety, pharmacokinetics (PK), pharmacodynamics, and preliminary
      efficacy of ABBV-927 with ABBV-368, Budigalimab (ABBV-181) and/or chemotherapy in
      participants with selected solid tumors. This study consists of 2 main parts, a
      dose-escalation phase and a dose-expansion phase. The dose-expansion phase can begin once the
      recommended phase 2 dose/maximum tolerated dose (RP2D/MTD) is determined in the
      dose-escalation phase.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 21, 2019</start_date>
  <completion_date type="Anticipated">November 26, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 11, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Expansion: Objective Response Rate (ORR)</measure>
    <time_frame>Up to approximately 2 years following the first dose of study drug</time_frame>
    <description>ORR is defined as the percentage of participants with either complete response (CR) or partial response (PR) based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-Escalation Phase: Recommended Phase 2 Dose (RP2D) of ABBV-927 + ABBV-368</measure>
    <time_frame>Up to approximately 6 months</time_frame>
    <description>The RP2D of ABBV-927 + ABBV-368 will be determined during the dose-escalation phase of the study. RP2D will be determined using available safety and pharmacokinetics data.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-Escalation Phase: Recommended Phase 2 Dose (RP2D) of ABBV-927 + ABBV-368 + ABBV-181</measure>
    <time_frame>Up to approximately 6 months</time_frame>
    <description>The RP2D of ABBV-927 + ABBV-368 + ABBV-181 will be determined during the dose-escalation phase of the study. RP2D will be determined using available safety and pharmacokinetics data.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dose-Expansion Phase: Progression-free Survival (PFS)</measure>
    <time_frame>Up to approximately 2 years since the first dose of study drug</time_frame>
    <description>PFS is defined as the time from date of first study drug exposure to disease progression or death, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose-Expansion Phase: Duration of Response (DOR)</measure>
    <time_frame>Up to approximately 2 years since the first dose of study drug</time_frame>
    <description>DOR defined as the time from the participant's initial response to study drug therapy to disease progression or death, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Serum Concentration (Cmax)</measure>
    <time_frame>Up to approximately 12 weeks after participant's initial dose of study drug</time_frame>
    <description>Maximum Serum Concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Observed Serum Concentration (Tmax)</measure>
    <time_frame>Up to approximately 12 weeks after participant's initial dose of study drug</time_frame>
    <description>Time to Maximum Observed Serum Concentration (Tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Serum Concentration Versus Time Curve from Time 0 to the Time of the Last Measurable Concentration (AUCτ)</measure>
    <time_frame>Up to approximately 12 weeks after participant's initial dose of study drug</time_frame>
    <description>Area under the serum concentration versus time curve from time 0 to the time of the last measurable concentration (AUCτ).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Phase Elimination Half-life (t1/2)</measure>
    <time_frame>Up to approximately 4 weeks after participant's initial dose of study drug</time_frame>
    <description>Terminal Phase Elimination Half-life (t1/2)</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Cancer</condition>
  <condition>Advanced Solid Tumors</condition>
  <condition>Triple-Negative Breast Cancer (TNBC)</condition>
  <condition>Non-small-cell-lung-cancer (NSCLC)</condition>
  <condition>Metastatic Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Dose Escalation Arm A: ABBV-927 + ABBV-368 Solid Tumors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with Solid Tumors will receive various doses of ABBV-927 by intravenous (IV) infusion plus ABBV-368. This will determine the recommended phase two dose (RP2D) of ABBV-927.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Escalation Arm B: ABBV-927 + ABBV-368 + ABBV-181 NSCLC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with non-small-cell-lung-cancer (NSCLC) will receive ABBV-927 IV at various dose levels + ABBV-368 + ABBV-181. This will determine the recommended phase two dose (RP2D) of ABBV-927 + ABBV-368 + ABBV-181.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion Arm 1: ABBV-927 + Carboplatin + ABBV-368 TNBC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with Triple Negative Breast Cancer (TNBC) will receive ABBV-927 (at the RP2D established in Arm A) + Carboplatin + ABBV-368 by IV.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion Arm 2: ABBV-927 + Carboplatin + ABBV-181 TNBC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with TNBC will receive ABBV-927 (at the RP2D established in Arm A) + Carboplatin + ABBV-181 by IV.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion Arm 3: ABBV-927 + Carboplatin TNBC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with TNBC will receive ABBV-927 (at the RP2D established in Arm A) + Carboplatin by IV.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion Arm 4: ABBV-927+ Nab-paclitaxel + ABBV-368 TNBC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with TNBC will receive ABBV-927 (at the RP2D established in Arm A) + Nab-paclitaxel + ABBV-368 by IV.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion Arm 5: ABBV-927 + ABBV-368 + ABBV-181 NSCLC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with NSCLC will receive ABBV-927 (at the RP2D established in Arm B) + ABBV-368 + ABBV-181 by IV.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABBV-927</intervention_name>
    <description>Intravenous (IV) Infusion</description>
    <arm_group_label>Dose Escalation Arm A: ABBV-927 + ABBV-368 Solid Tumors</arm_group_label>
    <arm_group_label>Dose Escalation Arm B: ABBV-927 + ABBV-368 + ABBV-181 NSCLC</arm_group_label>
    <arm_group_label>Dose Expansion Arm 1: ABBV-927 + Carboplatin + ABBV-368 TNBC</arm_group_label>
    <arm_group_label>Dose Expansion Arm 2: ABBV-927 + Carboplatin + ABBV-181 TNBC</arm_group_label>
    <arm_group_label>Dose Expansion Arm 3: ABBV-927 + Carboplatin TNBC</arm_group_label>
    <arm_group_label>Dose Expansion Arm 4: ABBV-927+ Nab-paclitaxel + ABBV-368 TNBC</arm_group_label>
    <arm_group_label>Dose Expansion Arm 5: ABBV-927 + ABBV-368 + ABBV-181 NSCLC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABBV-368</intervention_name>
    <description>Intravenous (IV) Infusion</description>
    <arm_group_label>Dose Escalation Arm A: ABBV-927 + ABBV-368 Solid Tumors</arm_group_label>
    <arm_group_label>Dose Escalation Arm B: ABBV-927 + ABBV-368 + ABBV-181 NSCLC</arm_group_label>
    <arm_group_label>Dose Expansion Arm 1: ABBV-927 + Carboplatin + ABBV-368 TNBC</arm_group_label>
    <arm_group_label>Dose Expansion Arm 4: ABBV-927+ Nab-paclitaxel + ABBV-368 TNBC</arm_group_label>
    <arm_group_label>Dose Expansion Arm 5: ABBV-927 + ABBV-368 + ABBV-181 NSCLC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABBV-181</intervention_name>
    <description>Intravenous (IV) Infusion</description>
    <arm_group_label>Dose Escalation Arm B: ABBV-927 + ABBV-368 + ABBV-181 NSCLC</arm_group_label>
    <arm_group_label>Dose Expansion Arm 2: ABBV-927 + Carboplatin + ABBV-181 TNBC</arm_group_label>
    <arm_group_label>Dose Expansion Arm 5: ABBV-927 + ABBV-368 + ABBV-181 NSCLC</arm_group_label>
    <other_name>Budigalimab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Intravenous (IV) Infusion</description>
    <arm_group_label>Dose Expansion Arm 1: ABBV-927 + Carboplatin + ABBV-368 TNBC</arm_group_label>
    <arm_group_label>Dose Expansion Arm 2: ABBV-927 + Carboplatin + ABBV-181 TNBC</arm_group_label>
    <arm_group_label>Dose Expansion Arm 3: ABBV-927 + Carboplatin TNBC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab-paclitaxel</intervention_name>
    <description>Intravenous (IV) Infusion</description>
    <arm_group_label>Dose Expansion Arm 4: ABBV-927+ Nab-paclitaxel + ABBV-368 TNBC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adequate liver, kidney and hematology function as demonstrated by laboratory values
             detailed in the study protocol.

          -  An Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

        Dose-Escalation:

          -  Arm A: Participants with an advanced solid tumor who have progressed on standard
             therapies known to provide clinical benefit and/or participants who have refused or
             are intolerant of such therapy.

          -  Arm B (non-small-cell-lung-cancer [NSCLC]): Participants with histologically or
             cytologically confirmed NSCLC who previously progressed during or after an
             anti-programmed cell death (PD)-1 or PD ligand 1 (PD-L1) therapy and a platinum-based
             regimen in the recurrent or metastatic setting.

        Dose-Expansion:

          -  Arm 1, 2, and 3 (triple-negative breast cancer [TNBC]): Participants with
             histologically or cytologically confirmed breast adenocarcinoma that is estrogen
             receptor/progesterone receptor/human epidermal growth factor receptor (HER)2-negative
             who must have disease progression during or after at least 1 systemic therapy that
             included a taxane in the metastatic or recurrent setting and who are treatment-naïve
             to immunotherapy.

          -  Arm 4 (TNBC): Participants with histologically or cytologically confirmed TNBC who
             have received no previous anti-cancer therapy for TNBC, and who are PD-L1 negative on
             tumor tissue by immunohistochemistry (IHC) assay.

          -  Arm 5 (NSCLC): Participants with histologically or cytologically confirmed NSCLC who
             previously progressed either during or after an anti-PD-1 or PD-L1 therapy and a
             platinum-based regimen in the recurrent or metastatic setting.

        Exclusion Criteria:

          -  Has history of inflammatory bowel disease or pneumonitis.

          -  Has uncontrolled metastases to the central nervous system.

          -  Has a concurrent malignancy that is clinically significant, treatment is required, or
             the participant is not clinically stable.

          -  Has had a major surgery ≤ 28 days prior to the first dose of study drug or the
             surgical wound is not fully healed.

          -  Has previously treated with an anti-PD- or PD-L1-targeting agent and had during the
             course of their therapy:

          -  any immune-mediated toxicity of Grade 3 or worse severity

          -  treatment of the toxicity with systemic corticosteroids

          -  any hypersensitivity to the PD-1 or PD-L1-targeting agent

          -  any treatment-related toxicity resulting in discontinuation of the PD-1 or PD-L1
             targeting agent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ABBVIE CALL CENTER</last_name>
    <phone>847.283.8955</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>St Jude Hospital dba St Joseph /ID# 211130</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yale University /ID# 210678</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Carolina BioOncology Institute /ID# 210664</name>
      <address>
        <city>Huntersville</city>
        <state>North Carolina</state>
        <zip>28078</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Cancer Research /ID# 210716</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>NEXT Oncology /ID# 210717</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists /ID# 210671</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy /ID# 213052</name>
      <address>
        <city>Villejuif</city>
        <state>Ile-de-France</state>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut de Cancer de l'Ouest /ID# 212880</name>
      <address>
        <city>Angers</city>
        <zip>49055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Bichat-Claude Bernard /ID# 212869</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center /ID# 211699</name>
      <address>
        <city>Ramat Gan</city>
        <zip>5262100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d'Hebron /ID# 212804</name>
      <address>
        <city>Barcelona</city>
        <zip>8035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundacion Jimenez Diaz /ID# 212806</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hosp Univ Madrid Sanchinarro /ID# 212805</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital /ID# 210994</name>
      <address>
        <city>Tainan City</city>
        <state>Tainan</state>
        <zip>70403</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital /ID# 210993</name>
      <address>
        <city>Taipei City</city>
        <state>Taipei</state>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
    <country>Israel</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 27, 2019</study_first_submitted>
  <study_first_submitted_qc>March 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 28, 2019</study_first_posted>
  <last_update_submitted>March 9, 2020</last_update_submitted>
  <last_update_submitted_qc>March 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>Advanced Solid Tumors</keyword>
  <keyword>Triple-Negative Breast Cancer (TNBC)</keyword>
  <keyword>Non-small-cell-lung-cancer (NSCLC)</keyword>
  <keyword>ABBV-927</keyword>
  <keyword>ABBV-368</keyword>
  <keyword>ABBV-181</keyword>
  <keyword>metastatic solid tumors</keyword>
  <keyword>dose-escalation</keyword>
  <keyword>recommended phase 2 dose</keyword>
  <keyword>budigalimab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

